ATXS

11.51

0.26% -0.03

Handel nachbörslich: 11.50 -0.010 -0.09%

Astria Therapeutics Inc (ATXS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$11.54

Offen:

$11.49

24-Stunden-Volumen:

133.55K

Relative Volume:

0.42

Marktkapitalisierung:

$649.45M

Einnahmen:

Nettoeinkommen (Verlust:

$-72.89M

KGV:

-4.7172

EPS:

-2.44

Netto-Cashflow:

$-68.47M

1W Leistung:

-4.00%

1M Leistung:

-3.03%

6M Leistung:

+20.52%

1J Leistung:

+133.00%

1-Tages-Spanne:

$11.19

$11.64

1-Wochen-Bereich:

$11.01

$12.52

52-Wochen-Spanne:

$4.26

$16.90

Astria Therapeutics Inc Stock (ATXS) Company Profile

Firmenname

Astria Therapeutics Inc

Sektor

Healthcare (1182)

Branche

Biotechnology (671)

Telefon

617-349-1971

Adresse

22 BOSTON WHARF ROAD, BOSTON

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-11

Neueste SEC-Einreichungen

ATXS's Discussions on Twitter

Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-07-29	Eingeleitet	TD Cowen	Buy
2023-03-28	Eingeleitet	Evercore ISI	Outperform

Astria Therapeutics Inc Aktie (ATXS) Neueste Nachrichten

02:11 AM

Vanguard Group Inc's Strategic Acquisition in Astria Therapeutics Inc - GuruFocus.com

02:11 AM

Nov 04, 2024

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - XM

Nov 04, 2024

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Nov 04, 2024

Oct 30, 2024

Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting - Business Wire

Oct 30, 2024

Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of "Buy" from Analysts - MarketBeat

Oct 30, 2024

Oct 26, 2024

Objective long/short (ATXS) Report - Stock Traders Daily

Oct 26, 2024

Oct 24, 2024

Astria Therapeutics (NASDAQ:ATXS) Shares Up 6.8%Here's What Happened - MarketBeat

Oct 24, 2024

Oct 23, 2024

Astria Therapeutics (NASDAQ:ATXS) Share Price Crosses Below 50 Day Moving AverageHere's Why - MarketBeat

Oct 23, 2024

Oct 21, 2024

Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting - Business Wire

Oct 21, 2024

Oct 18, 2024

Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth - Yahoo Finance

Oct 18, 2024

Oct 17, 2024

European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics’ Investigational Therapy for the Treatment of Hereditary Angioedema - BioSpace

Oct 17, 2024

Oct 16, 2024

Astria Therapeutics gains orphan drug status in EU for HAE treatment - Investing.com Australia

Oct 16, 2024

Oct 15, 2024

(ATXS) Trading Report - Stock Traders Daily

Oct 15, 2024

Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Update - MarketBeat

Oct 15, 2024

Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Down 9.2% in September - MarketBeat

Oct 15, 2024

Oct 14, 2024

Astria Therapeutics (NASDAQ:ATXS) Stock Price Down 4.1%Should You Sell? - MarketBeat

Oct 14, 2024

Oct 13, 2024

Renaissance Technologies LLC Decreases Stock Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World

Oct 13, 2024

Dimensional Fund Advisors LP Buys 133,379 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat

Oct 13, 2024

Oct 12, 2024

Cubist Systematic Strategies LLC Purchases New Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat

Oct 12, 2024

Oct 11, 2024

Astria Therapeutics (NASDAQ:ATXS) Trading 5.2% HigherHere's What Happened - MarketBeat

Oct 11, 2024

Oct 06, 2024

Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Purchased by Millennium Management LLC - MarketBeat

Oct 06, 2024

Oct 05, 2024

Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Rating of "Buy" by Analysts - MarketBeat

Oct 05, 2024

Oct 02, 2024

Insider Sale Alert: Astria Therapeutics Inc [ATXS] – Is it Time to sell? - Knox Daily

Oct 02, 2024

Oct 01, 2024

Nantahala Capital Management LLC Makes New $6.14 Million Investment in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World

Oct 01, 2024

Are Astria Therapeutics Inc (ATXS) shares a good deal now? - US Post News

Oct 01, 2024

Closing Figures Unveiled: Astria Therapeutics Inc (ATXS) Drop -1.17, Closes at 11.01 - The Dwinnex

Oct 01, 2024

Logos Global Management LP Decreases Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat

Oct 01, 2024

Sep 30, 2024

ATXSAstria Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Sep 30, 2024

Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema - StockTitan

Sep 30, 2024

Cubist Systematic Strategies LLC Invests $2.56 Million in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat

Sep 30, 2024

Sep 29, 2024

Driehaus Capital Management LLC Sells 15,057 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World

Sep 29, 2024

Sep 27, 2024

Astria Therapeutics (NASDAQ:ATXS) Earns Buy Rating from HC Wainwright - MarketBeat

Sep 27, 2024

Astria Therapeutics to Present at Upcoming Global Angioedema Forum - StockTitan

Sep 27, 2024

Sep 26, 2024

Financial Snapshot: Analyzing Astria Therapeutics Inc (ATXS)’s Key Ratio Metrics - The Dwinnex

Sep 26, 2024

ATXS’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle

Sep 26, 2024

Sep 25, 2024

Astria Therapeutics (NASDAQ:ATXS) Shares Gap Down to $12.50 - MarketBeat

Sep 25, 2024